Research
Hormonal
Metformin treatment alters gut microbiota composition (increasing Escherichia coli and decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.
If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fatty acids. This is a key part of how the drug works, though it can cause temporary stomach upset for some people.
GoodSupportsHIGH confidence
Support for the causal effects of these GM differences in type 2 diabetes has been provided by randomized trials and studies in drug-naive individuals demonstrating that the GM compositional changes translate to enhanced production of propionate and butyrate (20,21) and modulation of bile acid pools (21), which may mediate some of the glucose-lowering effects of metformin (Fig. 3) (20–22,24).
Why this rating
Supported by randomized trials and large metagenomic studies, though individual variability exists.
Source
The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 <i>Diabetes</i>, <i>Diabetes Care</i>, and <i>Diabetologia</i> Expert Forum
Mariana X. Byndloss et al. · Diabetes · 2024
DOI 10.2337/dbi24-0028
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut microbiota composition determines individual variability in postprandial glycemic responses to standardized meals, enabling prediction of glucose spikes via machine learning models trained on metagenomic data.Good
- Increased circulating levels of branched-chain amino acids (BCAAs) and imidazole propionate, linked to gut microbiota function, are associated with insulin resistance and higher risk of type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →